Hepatocellular carcinoma is malignancy that originates from the liver.

Physical signs are hepatomegaly and ascites. It is usually asymptomatic for much of its natural history.

Liver cancer is the second most common cause of cancer-related mortality worldwide & hepatocellular carcinoma accounts for >90% of liver cancers.


Hepatocellular Carcinoma Drug Information

Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Monotherapy or in combination w/ paclitaxel for adult patients w/ advanced gastric cancer or gastro-oesophagea...


Indication: Progressive, locally advanced or metastatic, differentiated thyroid carcinoma (DTC), refractory to radioactive...

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum based chemother...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid (FA) for adjuvant treatment of stage III (Duke's C)...

Indication: In combination w/ other medicinal products for chronic hepatitis C (CHC) in adults.

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 02 Sep 2020
Proton beam radiotherapy (PBT) was noninferior to radiofrequency ablation (RFA) for local progression-free survival (LPFS) in patients with recurrent hepatocellular carcinoma (rHCC), in addition to showing a tolerable safety profile, according to the APROH trial presented during the 2020 digital ILC.
Elaine Soliven, 11 Sep 2020
Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.